Metabolic Messengers: ketone bodies

AB Nelson, ED Queathem, P Puchalska… - Nature …, 2023 - nature.com
Prospective molecular targets and therapeutic applications for ketone body metabolism
have increased exponentially in the past decade. Initially considered to be restricted in …

Ketogenic metabolic therapy for chronic kidney disease–the pro part

T Weimbs, J Saville, K Kalantar-Zadeh - Clinical Kidney Journal, 2024 - academic.oup.com
Ketogenic metabolic therapy (KMT) is a medical nutrition therapy to address certain health
and disease conditions. It is increasingly used for many non-communicable diseases that …

[HTML][HTML] Feasibility and impact of ketogenic dietary interventions in polycystic kidney disease: KETO-ADPKD—a randomized controlled trial

S Cukoski, CH Lindemann, S Arjune, P Todorova… - Cell Reports …, 2023 - cell.com
Ketogenic dietary interventions (KDIs) are beneficial in animal models of autosomal-
dominant polycystic kidney disease (ADPKD). KETO-ADPKD, an exploratory, randomized …

Short-term dapagliflozin administration in autosomal dominant polycystic kidney disease—a retrospective single-arm case series study

F Morioka, S Nakatani, H Uedono, A Tsuda… - Journal of Clinical …, 2023 - mdpi.com
Treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitors may have pleiotropic and
beneficial effects in terms of ameliorating of risk factors for the progression of autosomal …

Cleavage fragments of the C-terminal tail of polycystin-1 are regulated by oxidative stress and induce mitochondrial dysfunction

H Pellegrini, EH Sharpe, G Liu, E Nishiuchi… - Journal of Biological …, 2023 - ASBMB
Mutations in the gene encoding polycystin-1 (PC1) are the most common cause of
autosomal dominant polycystic kidney disease (ADPKD). Cysts in ADPKD exhibit a Warburg …

RESET-PKD: a pilot trial on short-term ketogenic interventions in autosomal dominant polycystic kidney disease

S Oehm, K Steinke, J Schmidt, S Arjune… - Nephrology Dialysis …, 2023 - academic.oup.com
Background Ketogenic dietary interventions (KDI) have been shown to be effective in animal
models of polycystic kidney disease (PKD), but data from clinical trials are lacking. Methods …

[HTML][HTML] β-hydroxybutyrate recapitulates the beneficial effects of ketogenic metabolic therapy in polycystic kidney disease

JA Torres, N Holznecht, DA Asplund, BC Kroes… - Iscience, 2024 - cell.com
Autosomal-dominant polycystic kidney disease (ADPKD) is a common monogenic disease
characterized by the formation of fluid-filled renal cysts, loss of mitochondrial function …

A kidney-specific fasting-mimicking diet induces podocyte reprogramming and restores renal function in glomerulopathy

V Villani, CN Frank, P Cravedi, X Hou, S Bin… - Science Translational …, 2024 - science.org
Cycles of a fasting-mimicking diet (FMD) promote regeneration and reduce damage in the
pancreases, blood, guts, and nervous systems of mice, but their effect on kidney disease is …

Autosomal dominant polycystic kidney disease therapies on the horizon

JX Zhou, VE Torres - Advances in Kidney Disease and Health, 2023 - Elsevier
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the formation of
numerous kidney cysts which leads to kidney failure. ADPKD is responsible for …

Ren. Nu, a dietary program for individuals with autosomal-dominant polycystic kidney disease implementing a sustainable, plant-focused, kidney-safe, ketogenic …

DM Bruen, JJ Kingaard, M Munits, CS Paimanta… - Kidney and …, 2022 - mdpi.com
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited
cause of renal failure and has limited pharmacological treatment options. Disease …